Can you stay on Wegovy indefinitely — and should you?

The NHS route has a two-year ceiling, private treatment is a different conversation

This is probably the biggest source of confusion people encounter, so it is worth clearing up directly. Under NICE's appraisal of semaglutide (TA875), the NHS recommends Wegovy for a maximum of two years, used within a specialist weight management service with multidisciplinary support. That is a funding and commissioning decision, not a pharmacological one. It tells us what the NHS will pay for; it does not tell us that the medicine becomes unsafe or ineffective at month twenty-five.

Private treatment sits outside that framework. There is no statutory two-year rule for a private prescriber working within the Wegovy SmPC. What matters privately is whether you still meet the clinical criteria, whether you are still responding, and whether any new health information changes the risk-benefit picture. That assessment needs to happen at every repeat, not as a formality, but as genuine clinical oversight.

If you are already on Wegovy through a private service and wondering about the long road ahead, the Wegovy treatment overview covers what the private pathway looks like from start to ongoing supply, and what long-term use looks like in practice goes into more detail on monitoring.

Weight tends to return when treatment stops, that evidence is clear

A common misconception is that once you have lost the weight, Wegovy has done its job and you can stop. The STEP 1 extension trial told a different story. Participants who stopped semaglutide at 68 weeks regained about two-thirds of the weight they had lost within a year, without any changes to their behaviour. That is not a failure of willpower; it reflects the biology of obesity, which semaglutide addresses whilst you take it rather than correcting permanently.

The NHS patient information for semaglutide notes that weight management medicines are most effective alongside sustained lifestyle changes, but it does not suggest that lifestyle changes alone reliably preserve weight lost whilst on a GLP-1 medicine once the medicine is withdrawn. This is the central reason many clinicians (and many patients) consider long-term use rather than treating it as a short course.

That biology also explains why the question of staying on Wegovy indefinitely is not a frivolous one. For some people the calculus is genuinely straightforward: the medicine is working, the side effects are manageable, and the health risks of regaining weight are significant. For others, the picture is more complex. A prescriber who knows your case can help you think through it properly.

What changes if you decide to stay on it: monitoring and suitability reviews

Continuing Wegovy is not a passive decision. At every clinical review (and a reputable service will insist on this before each repeat) your prescriber is checking a few things: whether your weight trajectory is still positive, whether any new symptoms or health changes affect suitability, and whether the dose you are on still makes sense. If you have been on the maximum tolerated dose for six months and seen less than 5% weight loss, that is the trigger point at which continuing is typically reconsidered under NICE criteria.

Side effects also evolve over time for some people. Gastrointestinal effects (nausea, changed bowel habits, early fullness) are most pronounced early in treatment and usually settle. Long-term users more often ask about things like muscle mass, nutrition adequacy, and what happens to appetite regulation if the medicine eventually stops. These are real questions worth raising with your prescriber.

The cost of ongoing treatment is a practical consideration too. A transparent breakdown of what private Wegovy supply costs over time is set out on the Wegovy prices page, which may help you plan. And if you want to understand the mechanism driving all of this in more depth, the semaglutide explainer covers how GLP-1 receptor agonism affects appetite and metabolism.

How a prescriber actually makes this call with you

No prescriber can tell you at the start of treatment exactly how long you will need Wegovy. What they can do is set up a review structure that keeps revisiting the question honestly. At nume, a clinician reads every repeat request before anything is dispensed, not a checklist passed to software, but a real prescriber applying clinical judgement. That structure matters for long-term users particularly, because the risk-benefit balance can shift.

The question of whether staying on Wegovy is strictly necessary is a good one to bring to that conversation. Some people find that they can gradually taper, maintain most of their progress, and come off treatment; others find the opposite. If you are newer to all of this, it is worth reading the semaglutide definition to get a clear grounding in what the medicine actually is before weighing up the longer-term options. The evidence base does not yet tell us reliably who will fall into which group, which is precisely why this should be an ongoing clinical conversation rather than a one-time decision made at month one.

If you are weighing up whether to start, continue or plan the long term, our prescribers are available every day. Start your free consultation and speak to a clinician who can look at your specific situation, not just the average trial participant.